Personalized rehabilitation exercises for nerve damage caused by chemotherapy
Tests a movement-guided exercise program in adults with chemotherapy-related nerve damage.
Plain-language title generated from the registry record
Registry title: Effectiveness of Video-Based Movement Analysis-Guided Personalized Rehabilitation in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Key facts
- Where
- Seongnam-si, South KoreaSee the site
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Bundang Hospital
- Trial code
- NCT07714278
- Record updated
- 14 August 2026
- Original description
This study aims to quantify motor control abnormalities using video-based movement analysis in patients with chemotherapy-induced peripheral neuropathy (CIPN) and to evaluate the effectiveness of an analysis-guided personalized rehabilitation intervention. The study enrolls adult patients diagnosed with breast cancer, colorectal cancer, or gynecological cancer.Read full original descriptionShow less
A Multicenter Investigator-Initiated Clinical Trial Evaluating the Effectiveness of Video-Based Movement Analysis-Guided Personalized Rehabilitation in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
This study aims to quantify motor control abnormalities using video-based movement analysis in patients with chemotherapy-induced peripheral neuropathy (CIPN) and to evaluate the effectiveness of an analysis-guided personalized rehabilitation intervention. The study enrolls adult patients diagnosed with breast cancer, colorectal cancer, or gynecological cancer.
This is a randomized crossover trial where participants have an equal (50%) chance of being assigned to either Group A or Group B. The total participation period for each participant is approximately 8 weeks, which includes outcome assessments at baseline, week 4, and week 8.
The study consists of two periods:
Phase 1 (First 4 weeks): Group A participates in the 'ReMAP' rehabilitation exercise program, while Group B receives usual care.
Phase 2 (Next 4 weeks): Group A switches to usual care, while Group B participates in the 'ReMAP' rehabilitation exercise program.
Inclusion: Adult patients aged 19 years or older; Diagnosed with breast cancer, colorectal cancer, or gynecological cancer, and currently receiving chemotherapy or under follow-up observation after completing treatment; History of treatment with neurotoxic chemotherapeutic agents (e.g., taxane, platinum, etc.) or experiencing related symptoms; Symptoms or risk of chemotherapy-induced peripheral neuropathy (CIPN) (NCI-CTCAE Grade >= 1); Able to walk independently (with or without assistive devices); Able to understand the study purpose and procedures and voluntarily provide written informed consent.
Exclusion: Severe central nervous system disorders (e.g., stroke, Parkinson's disease, etc.) or severe musculoskeletal disorders that make functional assessment or exercise performance difficult; Severe cognitive impairment that interferes with study participation or the ability to follow instructions; Recurrent or progressive cancer with an unstable general systemic condition; Any other condition or clinical reason that, in the opinion of the investigator, makes participation in the study inappropriate; Peripheral neuropathy clearly attributable to causes other than CIPN, such as diabetic neuropathy; Recent significant injury due to a fall, or cases where exercise performance is deemed medically unsafe.